

1 Title

2 A systematic review of the clinical profile of patients with bubonic plague and the outcome
3 measures used in research settings

4 Authors

5 Josephine Bourner^{1*}, Lovarivelo Andriamarohasina², Alex Salam¹, Nzelle Delphine Kayem¹, Rindra
6 Randremanana², Piero Olliaro¹

7 ¹ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK

8 ²Institut Pasteur de Madagascar, Antananarivo, Madagascar

9 *Corresponding author: josephine.bourner@ndm.ox.ac.uk

10 Abstract

11 **Background:** Plague is a zoonotic disease that, despite affecting humans for more than 5000 years,
12 has historically been the subject of limited drug development activity. Drugs that are currently
13 recommended in treatment guidelines have been approved based on animal studies alone – no
14 pivotal clinical trials in humans have yet been completed. As a result of the sparse clinical research
15 attention received, there are a number of methodological challenges that need to be addressed in
16 order to facilitate the collection of clinical trial data that can meaningfully inform clinicians and
17 policy-makers. One such challenge is the identification of clinically-relevant endpoints, which are
18 informed by understanding the clinical characterisation of the disease – how it presents and evolves
19 over time, and important patient outcomes, and how these can be modified by treatment.

20 **Methodology/ Principal findings:** This systematic review aims to summarise the clinical profile of
21 1343 patients with bubonic plague described in 87 publications, identified by searching bibliographic
22 databases for studies that meet pre-defined eligibility criteria. The majority of studies were

23 individual case reports. A diverse group of signs and symptoms were reported at baseline and post-
24 baseline timepoints – the most common of which was presence of a bubo, for which limited
25 descriptive and longitudinal information was available. Death occurred in 15% of patients; although
26 this varied from an average 10% in high-income countries to an average 17% in low- and middle-
27 income countries. The median time to death was 1 day, ranging from 0 to 16 days.

28 **Conclusions/ Significance:** This systematic review elucidates the restrictions that limited disease
29 characterisation places on clinical trials for infectious diseases such as plague, which not only
30 impacts the definition of trial endpoints but has the knock-on effect of challenging the interpretation
31 of a trial’s results. For this reason and despite interventional trials for plague having taken place,
32 questions around optimal treatment for plague persist.

33 Author summary

34 Plague is an infectious disease that, despite affecting humans for more than 5000 years, has
35 historically been the subject of limited drug development activity. In fact, the drugs currently used to
36 treat plague have been approved based on experimental data alone – no major clinical trials have
37 yet been completed that demonstrate the efficacy and safety of one treatment over another in
38 humans. A major barrier to accomplishing this is that few research studies have taken place to date
39 that can meaningfully inform the design of a clinical trial. We conducted this systematic review to
40 gather and summarise all the existing information on the clinical profile of plague patients to
41 understand whether sufficient information exists on which to design informative clinical trials that
42 would provide clinicians and policy-makers with the information needed to make treatment
43 decisions for patients.

44 This study however found that, based on the existing literature, there is insufficient data that can be
45 used to develop methodologies for future trials. Either time must be invested in to collecting robust

46 clinical data or innovative trial designs need to be identified that can simultaneously collect much-
47 needed observational data while also evaluating much-needed interventions.

48 Introduction

49 Plague is a zoonotic infectious disease caused by *Yersinia Pestis*, Gram-negative bacteria most
50 commonly found in small mammals and transmitted by fleas. [1]

51 Transmission to humans typically occurs following a bite from an infected flea, contact with
52 contaminated bodily fluids or tissues, or inhalation of respiratory droplets. [1] Once infected, human
53 plague manifests in three main clinical forms: bubonic, pneumonic and septicemic – the most
54 common of which is bubonic plague, but the disease can also progress to include secondary clinical
55 forms. [1, 2]

56 Other than characteristic swollen, painful lymph nodes – or “buboes” – symptoms of bubonic plague
57 are often non-specific and can typically include fever, headache, chills and weakness. [1, 2] Estimates
58 of the case fatality rate (CFR) of bubonic plague are wide-ranging, extending from 24% to 60%
59 overall [1, 3], but a lower CFR of ~5% has been reported in treated cases and in research settings. [4]

60 In 2018, the last year for which global data exists, 248 cases of plague were reported – 98% of which
61 derive from just two countries, Madagascar and the Democratic Republic of Congo. [5] However,
62 since 2013, cases have been consistently reported within a number of countries across Asia, North
63 America, South America, and Africa and the global distribution of natural plague foci is thought to
64 extend far beyond the countries that have recently reported cases. [5, 6] Due to the disease’s ability
65 to lie dormant for years and even decades, [7] there is potential for cases to arise in locations in
66 which plague has not been reported for a significant amount of time.

67 While several treatment regimens for plague are recommended in both national and international
68 treatment guidelines, there are no robust clinical data to support the drugs that are commonly used
69 in clinical practice against plague. No pivotal randomised controlled trials have successfully taken

70 place to generate sufficient evidence for plague treatment regimens. A number of drugs, such as
71 streptomycin, ciprofloxacin and doxycycline [8], have been approved for the treatment of plague
72 based on the U.S. Food and Drug Administration’s (FDA) so-called ‘Animal rule’ – which permits the
73 approval of drugs on the basis of well-controlled animal studies when human studies are neither
74 ethical nor feasible [9]. Other drugs, which have not received FDA approval, such as gentamicin, are
75 also commonly used to treat plague based on experimental data and clinical experience. [10]
76 Some of these drugs however have significant drawbacks. Until recently, guidelines relied heavily on
77 the use of aminoglycosides, with streptomycin in particular being the drug of choice for the
78 treatment of plague in many settings. [11] [12-14] While effective against Gram-negative bacterial
79 infections, patients treated with aminoglycosides are at higher risk of experiencing ototoxic or
80 nephrotoxic side effects than when treated with other drugs [15], requiring onerous clinical
81 monitoring – which many low-resource health facilities in areas with the highest burden of plague
82 are not equipped to carry out. Streptomycin also comes with a high cost and is currently in short
83 supply on the global market. Other treatment regimens, such as those using doxycycline, are
84 bacteriostatic, have only oral formulations available and therefore are not adapted for more severe
85 forms of plague. Both aminoglycosides and tetracyclines are contraindicated in pregnancy. [16]
86 Robust clinical studies are therefore required to identify safe and effective treatment regimens for
87 plague. To date, only a small number of interventional trials have attempted to evaluate the efficacy
88 of plague treatment regimens, two of which have published data. [4, 17] Neither of these studies
89 were able to generate sufficient evidence to demonstrate clinical benefit of their investigational
90 drugs. This is in part due to the low numbers of patients enrolled in the trials – five and 65 patients
91 were enrolled respectively – influenced by logistical challenges and the low numbers of cases
92 reported in the areas in which the studies were conducted. The other challenge is methodological.
93 One trial was designed as a non-randomised trial without a control group and the other was
94 designed to recruit a small number of cases – for which the sample size estimation was based on

95 data generated in a substantively different patient population – to assess a broadly-defined
96 composite endpoint of cure or improvement in condition.

97 It is therefore clear that more work needs to be done to refine clinical trial methodologies for
98 plague, keeping in mind the logistical challenges and the current low case numbers that might
99 prevent the success of large-scale trials. Understanding the clinical characterisation of plague would
100 be beneficial to overcoming some of the methodological challenges evident in the two studies
101 referenced above, such as identifying viable, clinically relevant endpoints.

102 This review therefore aims to summarise the clinical profile of patients with bubonic plague –
103 including clinical characteristics at baseline and post-treatment, and clinical outcomes – as described
104 in published, peer-reviewed scientific literature.

105 **Methods**

106 We conducted a systematic review to describe the clinical characteristics and outcomes of patients
107 with suspected or confirmed bubonic plague from presentation to last recorded observation.

108 A search was conducted on bibliographic databases and clinical trial registries, including PubMed,
109 Cochrane CENTRAL, clinicaltrials.gov, ISRCTN and the International Clinical Trials Registry Platform
110 (ICTRP) for peer-reviewed publications describing the clinical characteristics of patients with bubonic
111 plague. A supplementary search was conducted on JSTOR to identify older reports (pre-1970) of
112 plague, although no formal search was conducted to obtain these publications. A full list of search
113 terms and filters that were used for each database and registry can be found in **Text S1**.

114 To obtain data relating to the clinical characteristics of bubonic plague, all study designs were
115 eligible for inclusion providing the publication contained individual patient data for adults or children
116 of any age with suspected or confirmed bubonic plague, and described signs, symptoms and
117 outcomes. There were no restrictions placed on language or publication year. Non-human, non-
118 clinical, post-mortem and vaccine studies were excluded.

119 Two reviewers independently conducted screening in Rayyan [18] and was completed in two stages
120 by reviewing titles and abstracts then reviewing full-text articles of remaining publications. Data was
121 extracted by the first reviewer on to a standardised data capture form in Excel. A second reviewer
122 verified the search and performed a quality control review on 30% of the data records. Any
123 disagreement was discussed between the two reviewers and a third independent reviewer was
124 involved if a disagreement remained unresolved.

125 Risk of bias was evaluated within the included studies by one reviewer using the Joanna Briggs
126 Institute Critical Appraisal tools. [19] Case reports were assessed using the case reports tools,
127 randomised controlled trials were assessed using the randomised controlled trials tool and non-
128 randomised interventional studies were assessed using the quasi-experimental studies tool.

129 The protocol and data dictionary associated with this review can be accessed upon reasonable
130 request to the corresponding author.

131 Analysis

132 The analysis was completed using R v.4.2.2.

133 The screening and inclusion processes are summarised in the PRISMA flow diagram. A summary of
134 all included studies is provided in a table detailing the study title, study type, country in which the
135 study was conducted, number of bubonic plague cases in each study, the ratio of males to females,
136 and the median and range of ages of the study population in years.

137 Two bar charts summarise the number of included studies per year per country, and the size of the
138 patient population in the studies per year per country.

139 Demographic data were extracted from each study to summarise the ratio of males to females, and
140 age (median and range) across the entire patient population of all included studies. The total
141 number and percent of pregnant women and patients with comorbidities among the patient
142 population is also provided.

143 The signs and symptoms are summarised for patients who received a confirmed clinical or
144 laboratory diagnosis of bubonic plague and are reported at baseline and post-baseline timepoints.
145 Baseline is defined at the first interaction the patient has with a health professional and post-
146 baseline includes all timepoints that occur after the day of the initial interaction. Signs and
147 symptoms are summarised as the number and percentage of patients in whom each sign or
148 symptom was reported on at least one occasion. The denominator is based on the sum of the
149 sample sizes of studies in which at least one patient reported the sign or symptom; in order to
150 eliminate studies in which the sign or symptom may not have been assessed or captured during data
151 collection, studies which do not report the sign or symptom for at least one patient have been
152 excluded from the denominator calculation.

153 The number and percentage of patients receiving treatment or no treatment is provided. Treatment
154 information is summarised according to antimicrobial class, as defined in a recent systematic review
155 by the U.S. Centres for Disease Control and Prevention. [20] Aminoglycosides, tetracyclines,
156 fluoroquinolones, sulphonamides, and amphenicols were considered to be “high-efficacy”. All other
157 antimicrobials were classified as “other antibiotics”. The number and percentage of deaths among
158 those who received high-efficacy, other antibiotics or no treatment has been provided.

159 Patient outcomes are summarised as the number and percentage of deaths among the entire
160 patient population, and according to the patient population in studies taking place in high-income
161 countries and low- and middle-income countries. The outcome of the bubo – as present or not
162 present – at the last recorded observation has been reported as the number and percentage of
163 patients reporting the outcome among the patient population with a known bubo.

164 Results

165 In total, 2023 publications were identified in the search (Fig 1). After removing duplicates, 1984
 166 publications were screened for inclusion. Following title, abstract and full-text screening, 1897
 167 records were excluded, resulting in the inclusion of 87 publications for data synthesis.

168 Figure 1 – PRISMA 2020 Flow Diagram [21]

169 Of the included studies, 72 (83%) were case reports, 11 (13%) were cohort studies, four (4%) were
 170 interventional studies, of which one (1%) was randomised and three (3%) were non-randomised
 171 (Table 1).

172 Table 1 – Summary of included studies

Study title <i>First author, Year</i>	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median ^a (range)
Two Cases Of Bubonic Plague Occurring On Board Ship <i>Barnett H. N., 1902 [22]</i>	Case report(s)	United Kingdom	2	2: 0	NK
A case of bubonic plague on a vessel arriving in the Mersey <i>NK, 1905 [23]</i>	Case report(s)	United Kingdom	1	1: 0	NK
Subacute plague in man due to ground squirrel infection <i>McCoy G. W., 1909 [24]</i>	Case report(s)	United States	1	1: 0	13
Three Cases of Bubonic Plague Arising In England <i>Rendle-Short A., 1916</i>	Case report(s)	United Kingdom	3	3: 0	16 (10 to 23)
Streptomycin in Bubonic Plague <i>Haddad C. H., 1948 [25]</i>	Interventional, non-randomised	Israel	3	3: 0	20 (8 to 35)
Plague -- New Mexico <i>United States Centres for Disease Control and Prevention, 1965 [26]</i>	Case report(s)	United States	1	1: 0	14
Plague: Shasta County, California <i>United States Centres for Disease Control and Prevention, 1965</i>	Case report(s)	United States	1	1: 0	5
Suspected Case of Imported Bubonic Plague <i>United States Centres for Disease Control and Prevention, 1966</i>	Case report(s)	United States	1	1: 0	21
Plague -- Arizona <i>United States Centres for</i>	Case report(s)	United States	1	1: 0	4

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
<i>Disease Control and Prevention, 1967 [27]</i>					
Plague in San Diego <i>Connor J. D., 1968 [28]</i>	Case report(s)	United States	1	1: 0	3
Presumptive Bubonic Plague — Denver, Colorado <i>United States Centres for Disease Control and Prevention, 1968 [29]</i>	Case report(s)	United States	1	0: 1	6
Bubonic Plague Death -- Lemhi County, Idaho <i>United States Centres for Disease Control and Prevention, 1968 [30]</i>	Case report(s)	United States	1	1: 0	32
Plague Case -- Navajo Reservation -- Kayenta, Arizona <i>United States Centres for Disease Control and Prevention, 1968 [31]</i>	Case report(s)	United States	1	0: 1	8
Plague -- New Mexico <i>United States Centres for Disease Control and Prevention, 1969 [32]</i>	Case report(s)	United States	1	1: 0	3
Bubonic plague in the Southwestern United States <i>Reed W. P., 1970 [33]</i>	Case report(s)	United States	25	15: 10	14 (2 to 74)
Bubonic Plague – California <i>United States Centres for Disease Control and Prevention, 1970 [34]</i>	Case report(s)	United States	1	1: 0	8
Bubonic Plague – California <i>United States Centres for Disease Control and Prevention, 1970</i>	Case report(s)	United States	1	1: 0	45
Human Bubonic Plague -- Cochiti, New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [35]</i>	Case report(s)	United States	1	1: 0	39
Bubonic Plague -- Santa Fe, New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [36]</i>	Case report(s)	United States	1	0: 1	20
Plague -- New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [37]</i>	Case report(s)	United States	1	1: 0	13
Plague -- New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [38]</i>	Case report(s)	United States	2	1: 1	24.5 (15 to 34)

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
Plague -- California <i>United States Centres for Disease Control and Prevention, 1970 [39]</i>	Case report(s)	United States	1	0: 1	10
Plague - Rio en Medio, New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [40]</i>	Case report(s)	United States	1	0: 1	9
Plague – New Mexico <i>United States Centres for Disease Control and Prevention, 1970 [41]</i>	Case report(s)	United States	1	1: 1	11.5 (7 to 16)
Human Bubonic Plague – Oregon <i>United States Centres for Disease Control and Prevention, 1971 [42]</i>	Case report(s)	United States	1	1: 0	10
Human Bubonic Plague – New Mexico <i>United States Centres for Disease Control and Prevention, 1971 [43]</i>	Case report(s)	United States	1	0: 1	26
Clinical Features of Plague in the United States: the 1969-1970 Epidemic <i>Palmer D. L., 1971 [44]</i>	Cohort	United States	19	12: 7	25.5 (2 to 49)
Human Bubonic Plague - Coconino County Colorado <i>United States Centres for Disease Control and Prevention, 1972 [45]</i>	Case report(s)	United States	1	1: 0	19
Human Bubonic Plague – Arizona <i>United States Centres for Disease Control and Prevention, 1973 [46]</i>	Case report(s)	United States	1	0: 1	9
Co-trimoxazole in Bubonic Plague <i>Nguyen-Van-Ai, 1973 [47]</i>	Interventional, non-randomised	Vietnam	12	4: 8	38.5 (6 to 63)
Human Bubonic Plague – New Mexico <i>United States Centres for Disease Control and Prevention, 1974 [48]</i>	Case report(s)	United States	1	0: 1	12
Human Plague – New Mexico <i>United States Centres for Disease Control and Prevention, 1974 [49]</i>	Case report(s)	United States	1	1: 0	19
Human Plague – New Mexico, Utah <i>United States Centres for</i>	Case report(s)	United States	1	1: 0	5

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
<i>Disease Control and Prevention, 1974 [50]</i>					
Yersinia pestis Infection in Vietnam. I. Clinical and Hematologic Aspects <i>Butler T., 1974 [51]</i>	Cohort	Vietnam	22	17: 5	16 (4 to 67)
Plague and the gallium scan <i>Stahly T. L., 1975 [52]</i>	Case report(s)	United States	1	1: 0	11
Fatal Human Plague – California <i>United States Centres for Disease Control and Prevention, 1975 [53]</i>	Case report(s)	United States	1	0: 1	1
Bubonic Plague – Arizona <i>United States Centres for Disease Control and Prevention, 1975 [54]</i>	Case report(s)	United States	2	0: 2	17 (3 to 31)
Plague in Humans – New Mexico <i>United States Centres for Disease Control and Prevention, 1975 [55]</i>	Case report(s)	United States	6	0: 6	10.5 (3 to 28)
Human Plague Case -- Bernalillo County, New Mexico <i>United States Centres for Disease Control and Prevention, 1975 [56]</i>	Case report(s)	United States	1	1: 0	11
Bubonic Plague from Exposure to a Rabbit: A Documented Case, and a Review of Rabbit-Associated Plague Cases in The United States <i>Von Reyn C. F., 1976 [57]</i>	Case report(s)	United States	1	0: 1	62
Human Plague -- Arizona, California, New Mexico <i>United States Centres for Disease Control and Prevention, 1976 [58]</i>	Case report(s)	United States	3	2: 1	45 (15 to 63)
Yersinia pestis Infection in Vietnam. II; Quantitative Blood Cultures and Detection of Endotoxin in the Cerebrospinal Fluid of Patients with Meningitis <i>Butler T, 1976 [59]</i>	Cohort	Vietnam	42	20: 22	15 (3 to 70)
Plague and pregnancy. A case report <i>Mann J, 1977 [60]</i>	Case report(s)	United States	1	0: 1	28
Epidemiological and clinical features of an outbreak of bubonic plague in New Mexico <i>Von Reyn C. F., 1977 [61]</i>	Cohort	United States	7	3: 4	19 (5 to 62)

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
Plague -- Arizona, Colorado, New Mexico <i>United States Centres for Disease Control and Prevention, 1977 [62]</i>	Case report(s)	United States	4	3: 1	30.5 (3 to 43)
Plague – United States <i>United States Centres for Disease Control and Prevention, 1977 [63]</i>	Case report(s)	United States	1	1: 0	6
Plague -- Arizona, California, New Mexico <i>United States Centres for Disease Control and Prevention, 1978 [64]</i>	Case report(s)	United States	1	1: 0	14
Plague in the United States: the "black death" is still alive <i>Hoffman S. L., 1980 [65]</i>	Case report(s)	United States	1	1: 0	55
Plague -- United States <i>United States Centres for Disease Control and Prevention, 1980 [66]</i>	Case report(s)	United States	9	6: 3	8 (4 to 55)
Human Plague – Texas, New Mexico <i>United States Centres for Disease Control and Prevention, 1981 [67]</i>	Case report(s)	United States	1	1: 0	25
Human plague associated with domestic cats--California, Colorado <i>United States Centres for Disease Control and Prevention, 1981 [68]</i>	Case report(s)	United States	1	1: 0	49
Peripatetic Plague <i>Mann J., 1982 [69]</i>	Case report(s)	United States	1	0: 1	16
Febrile lymphadenitis in the American West <i>Mann J., 1982 [70]</i>	Case report(s)	United States	1	1: 0	5
Plague - South Carolina <i>United States Centres for Disease Control and Prevention, 1983 [71]</i>	Case report(s)	United States	1	0: 1	13
Plague in the United States 1982 <i>Barnes A. M., 1983 [72]</i>	Cohort	United States	19	11: 8	20 (4 to 78)
Plague Pneumonia – California <i>United States Centres for Disease Control and Prevention, 1984 [73]</i>	Case report(s)	United States	1	1: 0	35
Winter Plague -- Colorado, Washington, Texas, 1983-1984 <i>United States Centres for Disease Control and</i>	Case report(s)	United States	3	3: 0	38.5 (29 to 48)

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
<i>Prevention, 1984 [74]</i>					
Human Bubonic Plague Transmitted by a Domestic Cat Scratch <i>Weniger B. G., 1984 [75]</i>	Case report(s)	United States	1	0: 1	10
Nineteen cases of plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in pregnancy <i>Welty T. K., 1985 [76]</i>	Cohort	United States	19	6: 13	25 (2 to 78)
Multiple lung cavities in a 12-year-old girl with bubonic plague, sepsis, and secondary pneumonia <i>Florman A. L., 1986 [77]</i>	Case report(s)	United States	1	0: 1	12
Plague masquerading as gastrointestinal illness <i>Hull H. F., 1986 [78]</i>	Cohort	United States	47	NK: NK	61 (13 to 71)
Plague in a pregnant patient <i>Wong T. W., 1986 [79]</i>	Case report(s)	United States	1	0: 1	25
Plague meningitis--a retrospective analysis of cases reported in the United States, 1970-1979 <i>Becker T. M., 1987 [80]</i>	Case report(s)	United States	2	1: 1	10.5 (10 to 11)
Imaging in plague <i>Moreno A. J., 1987 [81]</i>	Case report(s)	United States	1	1: 0	8
Human Plague -- United States, 1988 <i>United States Centres for Disease Control and Prevention, 1988 [82]</i>	Case report(s)	United States	3	3: 0	41 (19 to 82)
Imported bubonic plague -- District of Columbia <i>United States Centres for Disease Control and Prevention, 1990 [83]</i>	Case report(s)	United States	1	0: 1	47
Bubonic plague in a child presenting with fever and altered mental status <i>Migden D., 1990 [84]</i>	Case report(s)	United States	1	1: 0	8
Plague in New Mexico <i>Owens C., 1990 [85]</i>	Case report(s)	United States	1	1: 0	47
Plague - A clinical review of 27 cases <i>Crook L. D., 1992 [86]</i>	Cohort	United States	27	15: 12	41 (2 to 80)
An Outbreak of Plague in Northwestern Province, Zambia <i>McClellan K. L., 1995 [87]</i>	Case report(s)	Zambia	1	1: 0	23
Fatal human plague--Arizona	Case report(s)	United States	2	1: 1	17 (16 to

Study title First author, Year	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median^a (range)
and Colorado, 1996 <i>United States Centres for Disease Control and Prevention, 1997 [88]</i>					18)
Current epidemiology of human plague in Madagascar <i>Chanteau S., 2000 [89]</i>	Cohort	Madagascar	917	515: 402	15 ^b
Cases of cat-associated human plague in the Western US, 1977-1998 <i>Gage K. L., 2000 [90]</i>	Case report(s)	United States	17	11: 6	28 (6 to 58)
Imported plague--New York City, 2002 <i>United States Centres for Disease Control and Prevention, 2003 [91]</i>	Case report(s)	United States	2	1: 1	50 (47 to 53)
Painful lymphadenopathy and fulminant sepsis in a previously healthy 16-year-old girl <i>Chmura K., 2003 [92]</i>	Case report(s)	United States	2	0: 1	16
Gentamicin and Tetracyclines for the Treatment of Human Plague: Review of 75 cases in New Mexico, 1985-1999 <i>Boulanger L. L., 2004 [93]</i>	Cohort	United States	50	31 :19	NK
Human plague--four states, 2006 <i>United States Centres for Disease Control and Prevention, 2006 [94]</i>	Case report(s)	United States	4	2: 2	34 (28 to 43)
Treatment of Plague with Gentamicin or Doxycycline in a Randomized Clinical Trial in Tanzania <i>Mwengee W., 2006 [4]</i>	Interventional, randomised controlled trial	Tanzania	65	41: 24	13 (0 to 65)
Notes from the field: two cases of human plague--Oregon, 2010 <i>United States Centres for Disease Control and Prevention, 2011 [95]</i>	Case report(s)	United States	2	NK: NK	29.5 (17 to 42)
Misidentification of <i>Yersinia pestis</i> by Automated Systems, Resulting in Delayed Diagnoses of Human Plague Infections—Oregon and New Mexico, 2010–2011 <i>Tourdjman M., 2012 [96]</i>	Case report(s)	United States	2	1: 1	37.5 (17 to 58)
Plague Outbreak in Libya, 2009, Unrelated to Plague in Algeria <i>Cabanel N., 2013[97]</i>	Cohort	Libya	2	1: 1	19 (14 to 24)

Study title <i>First author, Year</i>	Study type	Country	Bubonic plague cases reported, N	Sex, N male: N female	Age (years), Median ^a (range)
Outbreak of Plague in a High Malaria Endemic Region — Nyimba District, Zambia, March–May 2015 <i>Sinyange N., 2016 [98]</i>	Cohort	Zambia	7	NK: NK	8 (3 to 18)
Successful Treatment of Human Plague with Oral Ciprofloxacin <i>Apangu T., 2017 [17]</i>	Interventional, non-randomised	Uganda	4	1: 3	31 (10 to 52)
Case report <i>Lazet K., 2018</i>	Case report(s)	United States	1	0: 1	33
Human case of bubonic plague resulting from the bite of a wild Gunnison’s prairie dog during translocation from a plague endemic area <i>Melman S. D., 2018 [99]</i>	Case report(s)	United States	1	1: 0	66
Two fatal cases of plague after consumption of raw marmot organs <i>Kehrmann J., 2020 [100]</i>	Case report(s)	Mongolia	2	1: 1	37.5 (37 to 38)
Delays in Identification and Treatment of a Case of Septicemic Plague — Navajo County, Arizona, 2020 <i>Dale A. P., 2021 [101]</i>	Case report(s)	United States	1	1: 0	67

173 ^a Median and range only given where article includes >1 case of bubonic plague

174 ^b Only median age available

175

176 There was a moderate risk of bias across all study types (**Table S1; Fig S1**). Case reports contained
 177 limited demographic, treatment and follow-up information, although baseline signs and symptoms,
 178 and diagnostic information was well-described. In interventional and cohort studies, outcomes were
 179 generally reliably described and assessed, although the completeness of follow-up information was
 180 often unclear.

181 All studies were published between 1902 and 2021 (**Fig 2a**).

182 **Figure 2 – A) Number of studies included by country and by year; B) Number of patients reported**
 183 **by country and by year**

184 Of the 87 included studies, 73 (84%) were conducted in the United States, three (3%) in the United
185 Kingdom and Vietnam, two (2%) in Zambia, and 1 (1%) study each in Israel, Libya, Madagascar,
186 Mongolia, Tanzania, and Uganda (**Fig 2a**).

187 These studies contain data on 1343 probable and confirmed cases of bubonic plague (including
188 patients with secondary pneumonic or septicaemic plague). Of the included population, 870 (65%)
189 derive from one study conducted in Madagascar, 307 (23%) from studies conducted in the United
190 States, 76 (6%) from Vietnam, 65 (5%) from Tanzania, eight (1%) from Zambia, six (<1%) from each
191 the United Kingdom, four (<1%) from Uganda, three (<1%) from Israel, and two (<1%) from Mongolia
192 and Libya (**Fig 2b**).

193 However, over time the international distribution of included individuals has changed. From the
194 1960s to the 1980s reports of plague mainly derived from the United States; during this period, 209
195 (73%) individuals reported in this review were assessed in the United States (mostly in case reports
196 of single patients or case series of small numbers of patients), and the remainder in Vietnam. Since
197 the 1990s, the focus has shifted more towards the African region; during this time, 91% of cases
198 included in this review were assessed in Madagascar, Tanzania, Zambia, Uganda and Libya, with the
199 remainder assessed in the United States and Mongolia.

200 The study population consists of 769 (57%) males and 588 (43%) females with ages ranging from 0 to
201 82 years and a median age of 17 years. Among the population are five (<1%) patients who were
202 pregnant at the time of their plague diagnosis. Comorbidities were reported for 17 (<1%) patients,
203 including 13 (<1%) who tested positive for malaria. Other comorbidities include chronic cough,
204 chronic renal insufficiency, idiopathic thrombocytopenia, and heart murmur.

205 **Reported signs and symptoms**

206 **Baseline signs and symptoms:** The median time from symptom onset to admission was 2 days, with
207 a range of 0 to 18 days.

208 A diverse group of signs and symptoms were reported at baseline and post-baseline timepoints for
209 patients with confirmed bubonic plague within the articles included in this review (**Table S2**).

210 The most commonly reported symptom at baseline was the presence of a bubo – an enlarged lymph
211 node – which was recorded in 1216/1265 (96%) cases (**Table 1**). Of these cases, the median number
212 of buboes reported per patient was one. Nineteen patients reported having multiple buboes, for
213 whom the median number of buboes per patient was two. One patient was recorded as having 10
214 enlarged inguinal or suprapubic nodes, which were detected through the use of ultrasound. The
215 location of the bubo was reported in 1090 (90%) of these patients. Buboes were most commonly
216 reported in the inguinal area (590/1090, 54%), followed by the axillary (276/1090, 25%) and cervical
217 areas (159/1090, 15%), and less frequently in other locations, such as in femoral and epitrochlear
218 areas. Pain at the site of the bubo was recorded in 230/320 (72%) patients and bubo size was
219 infrequently recorded – 19/88 (22%) publications noted the size of at least one patient’s bubo. The
220 median recorded bubo size was 30mm, with a range of 1mm to 150mm. The method of bubo
221 measurement was reported only in one case report describing one patient, in which ultrasound was
222 used.

223 Following the presence of a bubo, fever was the most frequently reported systemic feature at
224 baseline, present in 1004/1279 (78%) patients, and for which the median recorded temperature was
225 39.5°C (range: 36°C to 103.2°C) (**Table 2**). Headache was present in 127/244 (52%) patients, followed
226 by altered mental status (33/84, 39%), chills (75/195, 38%) and malaise (22/68, 32%).

227 Fewer patients presented with clinical signs and symptoms indicative of severe illness at baseline,
228 such as seizure (4/34, 12%), septic shock (5/59, 8%), and respiratory distress, arrest or failure (3/5,
229 60%).

230 **Post-baseline signs and symptoms:** Reporting of signs and symptoms decreased following the
231 baseline assessment. Patients were followed up for a median of 7 days from admission (IQR 2 days
232 to 20 days).

233 Reports of fever and headache persisted each in 43% of patients, and there were infrequent reports
234 of other common symptoms at baseline, such as malaise, fatigue, abdominal pain, vomiting, cough,
235 nausea, hypotension, and diarrhoea. While altered mental status and chills were reported in
236 relatively high proportions of patients at baseline, no reports of these symptoms were made post-
237 baseline.

238 Only 19/88 (22%) articles provided information about the presence of the bubo at any timepoint
239 post-baseline for at least one patient in the study's cohort. Within this population, a persistent bubo
240 was recorded for 61/95 (64%) patient. A repeated bubo measurement is described in two case
241 reports, in which one repeated the measurement at 3 days post-baseline and demonstrated
242 increasing inguinal lymphadenopathy, which subsequently reduced to 10mm 26 days post-baseline –
243 a reduction of 25mm in total; and the other repeated the measurement at 29 days post-baseline and
244 demonstrated a reduction in size to 5mm – a decrease of 15mm from the baseline measurement –
245 from baseline in an axillary bubo which fully resolved at 39 days post-baseline. [75]

246 However, the frequency of some signs and symptoms indicative of severe illness increased. After the
247 baseline assessment, respiratory distress, arrest or failure, for example, was recorded in 8/65 (12%)
248 patients and disseminated intravascular coagulation was recorded in 7/41 (17%) patients.

249

250 **Table 2 – Reported signs and symptoms at baseline and post-baseline, N (%) patients**

	N (%) patients for whom symptom reported	
	Baseline	Post-baseline
Fever	1004/1279 (78%)	52/120 (43%)
<i>Temperature, °C (median, range)</i>	<i>39.5, 36 to 103.2</i>	-
Headache	127/244 (52%)	3/69 (43%)
Altered mental status	33/84 (39%)	-
Chills	75/195 (38%)	-
Malaise	22/68 (32%)	1/1 (100%)
Fatigue	6/22 (27%)	1/3 (33%)
Myalgia	54/204 (26%)	-
Abdominal pain	48/194 (25%)	2/2 (100%)
Vomiting	63/261 (24%)	5/70 (7%)
Sore throat	17/73 (23%)	-
Cough	37/167 (22%)	12/115 (10%)
Nausea	41/191 (21%)	1/65 (2%)
Hypotension	15/87 (17%)	11/85 (13%)
Diarrhoea	22/147 (15%)	3/67 (4%)
Seizure	4/34 (12%)	2/66 (3%)
Septic shock	5/59 (8%)	2/4 (50%)
Respiratory distress, arrest or failure	3/5 (60%)	8/65 (12%)
Disseminated intravascular coagulation	1/1 (100%)	7/41 (17%)
Bubo	1216/1265 (96%)	61/93 (64%)
<i>Axillary</i>	<i>276/1090 (25%)</i>	-
<i>Cervical</i>	<i>159/1090 (15%)</i>	-
<i>Inguinal</i>	<i>590/1090 (54%)</i>	-
<i>Other</i>	<i>65/1090 (6%)</i>	-
<i>Pain at bubo site</i>	<i>230/320 (72%)</i>	-
<i>Size, mm (median, range)</i>	<i>30, 1 to 150</i>	-

251

252 Outcome

253 An outcome was recorded for 1300/1343 (97%) patients. At the time of the last recorded
 254 observation (median: 7 days; range: 0 to 137 days), 1090/1343 (81%) had fully recovered and death
 255 was reported in 208/1343 (15%) patients (**Table 3**); however, the case fatality ratio but varied from
 256 10% for cases reported in high-income countries (HICs) to 17% in low- and middle-income countries
 257 (LMICs). The median time to death was 1 day in HICs and 2 days in LMICs, ranging from 0 to 16 days.

258 A bubo outcome was reported in 93/1279 (7%) cases in whom a bubo was reported at baseline. In
259 32/93 (34%) patients the bubo had completely disappeared at the last reported observation and in
260 61/93 (66%) cases the bubo was still present at the time of the last reported observation, which
261 ranged from 0 to 137 days post-admission.

262 **Table 3 – Summary of patient outcomes**

Outcome	n/N (%) patients
Death	208/1343 (15%)
<i>Time (days) from enrolment to death, median (range)</i>	<i>1 (0 to 16)</i>
Fully recovered at last reported observation	1090/1343 (81%)
<i>Time (days) to defervescence, median (range)</i>	<i>3.5 (0 to 21)</i>
Persistent bubo at last reported observation	61/93 (66%)

263

264 Treatment

265 Information on therapeutic intervention – or no intervention where specifically indicated – was
266 available for 305/1343 (23%) patients, of whom 271/305 (89%) received a high-efficacy antimicrobial
267 (with or without other antibiotics), 24/305 (8%) received only other antibiotics and 11/305 (4%)
268 received no antibiotics (**Table 4**).

269 Streptomycin was the most frequently administered high-efficacy plague therapeutic that was
270 administered – received by 141/305 (46%) patients either alone or in combination with other drugs
271 – followed by gentamicin, tetracycline and doxycycline received by 91/305 (30%), 85/305 (28%), and
272 42/305 (14%) patients, respectively. All other drugs were administered in small numbers of patients.
273 Of those who received a high-efficacy antimicrobial at any time following initial presentation, 15/271
274 (6%) died. Of the 24 patients who received only other antibiotics, 6 (25%) died and of the 11 patients
275 who received no antibiotic treatment, 5 (45%) died.

276

Table 4 – Summary of treatments received by number of patients and number of deaths

	Treatment with high-efficacy antibiotic											Other antibiotic treatment	No antibiotic treatment
	Streptomycin	Gentamicin	Levofloxacin	Doxycycline	Ciprofloxacin	Tetracycline	Chloramphenicol	Amikacin	Tobramycin	Trimethoprim-Sulfamethoxazole	Total		
n (%) patients N = 305	141 (46%)	91 (30%)	1 (<1%)	42 (14%)	8 (3%)	85 (28%)	5 (2%)	1 (<1%)	1 (<1%)	7 (2%)	271 (89%)	24 (8%)	11 (4%)
N deaths (CFR)*	6 (4%)	11 (12%)	0 (0%)	2 (5%)	0 (0%)	3 (4%)	5 (7%)	0 (0%)	0 (0%)	0 (0%)	15 (6%)	6 (25%)	5 (45%)

* T-test high-efficacy antibiotics v other antibiotics: $p = 0.08$; t-test high-efficacy antibiotics v no antibiotic treatment: $p = 0.04$.

1 Discussion

2 This systematic review was designed to summarise the clinical profile of patients with bubonic
3 plague, as described in academic literature, with the objective of clarifying the endpoint(s) that could
4 be used as the primary efficacy endpoint in therapeutic trials.

5 Overall the CFR that occurred across the patient population included in this review (15%) indicates
6 that mortality might not be a suitable primary endpoint for a clinical trial – a future trial using a
7 single mortality endpoint would likely require sample sizes that may not be attainable to detect
8 significant treatment effects between arms. A rough sample size estimation designed to detect a
9 50% reduction in mortality with a significance level of 5%, 80% power and 10% lost to follow-up
10 would yield a target sample size of 203 patients per arm, which might require several years to
11 complete, or not be attainable at all.

12 The data on CFR collected in the scope of this review – which varies according to context and type of
13 treatment received by the patient – may however not be representative of bubonic plague in the
14 21st century. The majority of included studies are case reports which derive from the United States
15 between the 1960s and 1980s and represent a large proportion of the patient population included in
16 this review. In 2018 however – the most recent year for which global data is available – 80% of the
17 global cases of plague derive from Madagascar, and a further 18% from the Democratic Republic of
18 Congo. These are two countries in which healthcare availability and accessibility may be substantially
19 different to that of the United States, which will likely influence patterns in disease presentation and
20 patient outcomes. In Madagascar, the CFR for patients with bubonic plague between 1998 and 2016
21 was reported to be 15%. [102] The study reporting this figure however cited several limitations in
22 that diagnostic testing evolved during the course of the study – meaning some earlier cases were
23 potentially missed due to the sub-optimal sensitivity of older testing methods – and that samples
24 from regions in Madagascar that had historically infrequently reported cases of plague were not

25 consistently available. The CFR was higher at 24% during a large, atypical urban plague outbreak that
26 occurred in 2017. [3] Uncertainty therefore still remains around the true incidence and CFR for
27 plague in the country with the greatest disease burden.

28 As survival or mortality may not be feasibly used as the single primary efficacy endpoint in a trial for
29 bubonic plague, alternative or additional clinically-relevant outcomes must be identified. The only
30 randomised controlled trial included in this review used “cure or improvement in condition” as its
31 primary endpoint – a composite outcome measure consisting of 1) fever resolution; 2) resolution of
32 bubo pain and swelling; 3) and recovery from pneumonia or any other symptom of plague present at
33 baseline. [4] An ongoing trial in Madagascar also uses a composite endpoint of therapeutic response
34 defined as 1) the patient being alive; 2) resolution of fever; 3) a 25% decrease in bubo size; 4)
35 alternative plague treatment not received; 5) no decision to continue treatment beyond day 10.

36 [103] Composite primary endpoints such as these provide a useful solution for diseases where low
37 numbers of individual events would prevent the detection of significant differences between arms in
38 a trial with a single endpoint. For example, by identifying several outcomes of interest, the number
39 of outcome events increases, therefore making it more likely that an effect can be detected with a
40 reasonable level of confidence.

41 Composite endpoints however also have the potential to introduce uncertainty around any
42 discernible differences that are detected and make the interpretation of the trial results challenging.
43 For example, the clinical relevance of the individual criteria that make up the above-referenced
44 composite endpoints is difficult to discern. Fever resolution, for example, was reported only for a
45 small proportion of patients (14%) included in this review, and although the event rate – 161/186
46 (87%) – was high, its relationship with a patient’s overall clinical status is unclear in the literature as
47 limited longitudinal data are available. The same can be said of the persistence or size of the bubo.
48 The breadth of the events included in the composite endpoint also create challenges for the
49 accurate interpretation of the trial’s results. The events range from resolution of fever to resolution

50 of pneumonia or any other symptom of plague. It is clear that the severity and clinical importance of
51 these events are vastly different. However, they are weighted equally in this composite endpoint
52 making it difficult to understand the true efficacy of the drug and how it works in this patient
53 population. In the event that Patient A presents with only a fever at baseline and Patient B presents
54 with pneumonia, fever and a bubo, can the recovery of both patients represent the true efficacy of
55 the drug?

56 While the urgency to provide results for plague, a disease with little evidence to support current
57 treatment recommendations, is understandable, critically, the relationship between individual signs,
58 symptoms and clinical status – as determined by both physical indicators of a patient’s condition and
59 laboratory testing for presence of *Y. pestis* in blood and/or bubo site – must be established before
60 implementing a primary outcome measure of this nature in a clinical trial.

61 Given the existing data, however, it is not currently possible to identify a single or composite
62 endpoint for plague, for which clinical relevance has been established and which would generate an
63 achievable sample size. It is clear that robust longitudinal data from an observational study would
64 provide critical information about the overall clinical course of plague illness and illuminate the
65 important outcomes that could be used in either a single or composite endpoint.

66 However, this will take a substantial amount of time – which could be better spent by taking a more
67 pragmatic approach to a trial. An approach recently proposed for Lassa fever, which exhibits similar
68 challenges in endpoint definition, is to embed an observational cohort within the trial framework to
69 collect data on patient outcomes. [104] The proposed design involves powering the trial for a
70 mortality endpoint, and in parallel identifying and collecting data on several important outcomes of
71 interest during the first year of the trial. An interim feasibility analysis would be undertaken to
72 determine whether the frequencies of the events are sufficient to generate an achievable sample
73 size and, if so, the trial would amend its primary endpoint. While this design has not been
74 implemented in a trial to date, it may provide a useful path forward for diseases such as plague

75 where little comparable data has been generated and uncertainty surrounds outcome frequencies.

76 This framework may provide a cost-saving and efficient approach to trials for diseases like plague

77 that could minimise delays to testing new drugs and reduce costs associated with implementing

78 both observational studies and trials sequentially.

79 Overall, this systematic review demonstrates the restrictions that limited disease characterisation

80 places on clinical trials for rare infectious diseases such as plague. The limited data that exist on the

81 clinical course of plague and patient outcomes, not only impact the definition of trial endpoints but

82 has the knock-on effect of challenging the interpretation of a trial's results. For this reason and

83 despite interventional trials for plague having taken place, questions around optimal treatment for

84 plague persist. Options however exist – including those for pragmatic and innovative trial designs. A

85 bigger challenge may however be to catalyse R&D interest in a disease for which there is limited

86 money to be made in the pharmaceutical industry.

87 Acknowledgements

88 The authors would like to thank Eli Harris for guidance and support to develop the search strategy in

89 this review.

90 This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome

91 (215091/Z/18/Z). The funder had no role in the design, conduct, analysis or manuscript preparation

92 of this systematic review. For the purpose of Open Access, the author has applied a CC BY public

93 copyright licence to any Author Accepted Manuscript version arising from this submission.

94 Competing interests

95 The authors of this manuscript declare no competing interests

96 Supplementary information

97 Text S1 – Search strategy

98 Table S1 – Risk of bias assessments

99 Fig S1 – Summary of risk of bias assessments

100 Table S4 -- Other reported signs and symptoms at baseline and post-baseline

101 References

102

- 103 1. World Health Organisation. Plague 2017 [30/11/2021]. Available from:
104 <https://www.who.int/news-room/fact-sheets/detail/plague>.
- 105 2. U.S. Centers for Disease Control and Prevention. Plague: Symptoms 2021 [30/11/2021].
106 Available from: <https://www.cdc.gov/plague/symptoms/index.html>.
- 107 3. Randremanana R, Andrianaivoarimanana V, Nikolay B, Ramasindrazana B, Paireau J, Ten
108 Bosch QA, et al. Epidemiological characteristics of an urban plague epidemic in Madagascar, August-
109 November, 2017: an outbreak report. *Lancet Infect Dis*. 2019;19(5):537-45. Epub 2019/04/02. doi:
110 10.1016/s1473-3099(18)30730-8. PubMed PMID: 30930106; PubMed Central PMCID:
111 PMC6483974.
- 112 4. Mwengee W, Butler T, Mgema S, Mhina G, Almasi Y, Bradley C, et al. Treatment of plague
113 with gentamicin or doxycycline in a randomized clinical trial in Tanzania. *Clin Infect Dis*.
114 2006;42(5):614-21. Epub 2006/02/01. doi: 10.1086/500137. PubMed PMID: 16447105.
- 115 5. Betherat E. Weekly Epidemiological Record: Plague around the world in 2019. World Health
116 Organisation, 2019.
- 117 6. World Health Organisation. Global Distribution of Natural Plague Foci as of March 2016.
118 2016.
- 119 7. Cabanel N, Leclercq A, Chenal-Francois V, Annajar B, Rajerison M, Bekkhoucha S, et al.
120 Plague outbreak in Libya, 2009, unrelated to plague in Algeria. *Emerging infectious diseases*.
121 2013;19(2):230-6. doi: 10.3201/eid1902.121031. PubMed PMID: 23347743.
- 122 8. U.S Food & Drug Administration. Products Approved for Other Bioterrorism Emergencies
123 2019 [30/11/2021]. Available from: [https://www.fda.gov/drugs/bioterrorism-and-drug-
124 preparedness/products-approved-other-bioterrorism-emergencies](https://www.fda.gov/drugs/bioterrorism-and-drug-preparedness/products-approved-other-bioterrorism-emergencies).
- 125 9. U.S. Food and Drug Administration. Animal Rule Information 2021 [30/11/2021]. Available
126 from: [https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-
127 science/animal-rule-information](https://www.fda.gov/emergency-preparedness-and-response/mcm-regulatory-science/animal-rule-information).
- 128 10. Nelson CA M-DD, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS. Antimicrobial Treatment
129 and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism
130 Response. *MMWR Recomm Rep*. 2021;70(RR-3):1–27. doi:
131 <http://dx.doi.org/10.15585/mmwr.rr7003a1>.
- 132 11. Godfred-Cato S, Cooley KM, Fleck-Derderian S, Becksted HA, Russell Z, Meaney-Delman D, et
133 al. Treatment of Human Plague: A Systematic Review of Published Aggregate Data on Antimicrobial
134 Efficacy, 1939–2019. *Clinical Infectious Diseases*. 2020;70(Supplement_1):S11-S9. doi:
135 10.1093/cid/ciz1230.
- 136 12. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Plague as a
137 biological weapon: medical and public health management. Working Group on Civilian Biodefense.

- 138 Jama. 2000;283(17):2281-90. Epub 2000/05/12. doi: 10.1001/jama.283.17.2281. PubMed PMID:
139 10807389.
- 140 13. Dennis DT, Gage KL, Gratz NG, Poland JD, Tikhomirov E, World Health Organization. Epidemic
141 Disease C. Plague manual : epidemiology, distribution, surveillance and control / principal authors:
142 David T. Dennis ... [et al.]. Geneva: World Health Organization; 1999.
- 143 14. U.S. Centers for Disease Control and Prevention. Recommended antibiotic treatment for
144 plague. 2006.
- 145 15. Jospe-Kaufman M, Siomin L, Fridman M. The relationship between the structure and toxicity
146 of aminoglycoside antibiotics. *Bioorg Med Chem Lett*. 2020;30(13):127218-. Epub 2020/04/25. doi:
147 10.1016/j.bmcl.2020.127218. PubMed PMID: 32360102.
- 148 16. Yu PA, Tran EL, Parker CM, Kim H-J, Yee EL, Smith PW, et al. Safety of Antimicrobials During
149 Pregnancy: A Systematic Review of Antimicrobials Considered for Treatment and Postexposure
150 Prophylaxis of Plague. *Clinical Infectious Diseases*. 2020;70(Supplement_1):S37-S50. doi:
151 10.1093/cid/ciz1231.
- 152 17. Apangu T, Griffith K, Abaru J, Candini G, Apio H, Okoth F, et al. Successful Treatment of
153 Human Plague with Oral Ciprofloxacin. *Emerg Infect Dis*. 2017;23(3):553-5. Epub 2017/01/27. doi:
154 10.3201/eid2303.161212. PubMed PMID: 28125398; PubMed Central PMCID: PMC5382724.
- 155 18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
156 systematic reviews. *Systematic Reviews*. 2016;5(1):210. doi: 10.1186/s13643-016-0384-4.
- 157 19. Institute JB. Critical Appraisal Tools [July 2021]. Available from: [https://jbi.global/critical-](https://jbi.global/critical-appraisal-tools)
158 [appraisal-tools](https://jbi.global/critical-appraisal-tools).
- 159 20. Kugeler KJ, Mead PS, Campbell SB, Nelson CA. Antimicrobial Treatment Patterns and Illness
160 Outcome Among United States Patients With Plague, 1942–2018. *Clinical Infectious Diseases*.
161 2020;70(Supplement_1):S20-S6. doi: 10.1093/cid/ciz1227.
- 162 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffman TC, Mulrow CD. The PRISMA 2020
163 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372(71). doi:
164 10.1136/bmj.n71.
- 165 22. Anderson TL. Two Cases of Bubonic Plague on Board Ship. *British Medical Journal*.
166 1902;2(2175):730-. doi: 10.1136/bmj.2.2175.730-b.
- 167 23. The Plague. A Case Of Bubonic Plague On A Vessel Arriving In The Mersey. *The British*
168 *Medical Journal*. 1905;1(2303):383-4.
- 169 24. McCoy GW, Wherry WB. Subacute Plague in Man Due to Ground Squirrel Infection. *The*
170 *Journal of Infectious Diseases*. 1909;6(5):670-5.
- 171 25. Haddad C, Valero A. Streptomycin in bubonic plague. *Br Med J*. 1948;1(4560):1026. Epub
172 1948/05/29. doi: 10.1136/bmj.1.4560.1026. PubMed PMID: 18860439; PubMed Central PMCID:
173 PMC2090756.
- 174 26. PLAGUE - New Mexico. Morbidity and Mortality. 1965;14(33):285-6.
- 175 27. PLAGUE — Arizona. Morbidity and Mortality. 1967;16(27):222-.
- 176 28. Connor JD, Williams RA, Thompson MA, Ginsberg M, Daley S. Plague in San Diego. *West J*
177 *Med*. 1978;129(5):394-406. Epub 1978/11/01. PubMed PMID: 726420; PubMed Central PMCID:
178 PMC1238391.
- 179 29. PRESUMPTIVE BUBONIC PLAGUE — Denver, Colorado. Morbidity and Mortality.
180 1968;17(27):253-60.
- 181 30. BUBONIC PLAGUE DEATH — Lemhi County, Idaho. Morbidity and Mortality. 1968;17(44):405-
182 6.
- 183 31. PLAGUE CASE - Navajo Reservation - Kayenta, Arizona. Morbidity and Mortality.
184 1968;17(29):269-70.
- 185 32. PLAGUE — New Mexico. Morbidity and Mortality. 1969;18(27):233-.
- 186 33. Reed WP, Palmer DL, Williams RCJ, Kisch AL. BUBONIC PLAGUE IN THE SOUTHWESTERN
187 UNITED STATES: A REVIEW OF RECENT EXPERIENCE. *Medicine*. 1970;49(6).
- 188 34. BUBONIC PLAGUE - California. Morbidity and Mortality. 1970;19(23):221-2.

- 189 35. HUMAN BUBONIC PLAGUE - Cochiti, New Mexico. Morbidity and Mortality.
190 1970;19(20):197-8.
- 191 36. BUBONIC PLAGUE – Santa Fe, New Mexico. Morbidity and Mortality. 1970;19(32):313-4.
- 192 37. PLAGUE - New Mexico. Morbidity and Mortality. 1970;19(25):241-2.
- 193 38. PLAGUE — New Mexico. Morbidity and Mortality. 1970;19(37):370-.
- 194 39. PLAGUE — California. Morbidity and Mortality. 1970;19(45):437-8.
- 195 40. PLAGUE — Rio en Medio, New Mexico. Morbidity and Mortality. 1970;19(33):322-.
- 196 41. PLAGUE — New Mexico. Morbidity and Mortality. 1970;19(28):270-1.
- 197 42. HUMAN BUBONIC PLAGUE – Oregon. Morbidity and Mortality. 1971;20(34):303-4.
- 198 43. HUMAN BUBONIC PLAGUE - New Mexico. Morbidity and Mortality. 1971;20(32):283-4.
- 199 44. Palmer DL, Kisch AL, Williams RC, Reed WP. Clinical Features of Plague in the United States:
200 The 1969-1970 Epidemic. *The Journal of Infectious Diseases*. 1971;124(4):367-71.
- 201 45. HUMAN BUBONIC PLAGUE - Coconino County, Arizona. Morbidity and Mortality.
202 1972;21(10):81-2.
- 203 46. HUMAN BUBONIC PLAGUE – Arizona. Morbidity and Mortality. 1973;22(30):249-50.
- 204 47. Nguyen Van A, Nguyen Duc H, Pham Van D, Nguyen Van L. Letter: Co-trimoxazole in bubonic
205 plague. *Br Med J*. 1973;4(5884):108-9. Epub 1973/10/13. doi: 10.1136/bmj.4.5884.108-c. PubMed
206 PMID: 4745331; PubMed Central PMCID: PMCPMC1587212.
- 207 48. HUMAN BUBONIC PLAGUE - New Mexico. Morbidity and Mortality. 1974;23(26):231-2.
- 208 49. HUMAN PLAGUE - New Mexico. Morbidity and Mortality. 1974;23(41):350-.
- 209 50. HUMAN PLAGUE — New Mexico, Utah. Morbidity and Mortality. 1974;23(37):317-8.
- 210 51. Butler T, Bell WR, Nguyen Ngoc L, Nguyen Dinh T, Arnold K. *Yersinia pestis* infection in
211 Vietnam. I. Clinical and hematologic aspects. *J Infect Dis*. 1974;129:Suppl:S78-84. Epub 1974/05/01.
212 doi: 10.1093/infdis/129.supplement_1.s78. PubMed PMID: 4825250.
- 213 52. Stahly TL, Shoop JD. Plague and the gallium scan: Case report. *J Nucl Med*. 1975;16(11):1031-
214 2. Epub 1975/11/01. PubMed PMID: 1185264.
- 215 53. FATAL BUBONIC PLAGUE - California. Morbidity and Mortality. 1975;24(24):211-.
- 216 54. BUBONIC PLAGUE – Arizona. Morbidity and Mortality. 1975;24(22):190-5.
- 217 55. PLAGUE IN HUMANS - New Mexico. Morbidity and Mortality. 1975;24(40):341-2.
- 218 56. HUMAN PLAGUE CASE – Bernalillo County, New Mexico. Morbidity and Mortality.
219 1975;24(10):90-5.
- 220 57. von Reyn CF, Barnes AM, Weber NS, Hodgins UG. Bubonic plague from exposure to a rabbit: a
221 documented case, and a review of rabbit-associated plague cases in the United States. *Am J*
222 *Epidemiol*. 1976;104(1):81-7. Epub 1976/07/01. doi: 10.1093/oxfordjournals.aje.a112276. PubMed
223 PMID: 937344.
- 224 58. Human Plague — Arizona, California, New Mexico. Morbidity and Mortality Weekly Report.
225 1976;25(19):155-.
- 226 59. Butler T, Levin J, Linh NN, Chau DM, Adickman M, Arnold K. *Yersinia pestis* infection in
227 Vietnam. II. Quantitative blood cultures and detection of endotoxin in the cerebrospinal fluid of
228 patients with meningitis. *J Infect Dis*. 1976;133(5):493-9. Epub 1976/05/01. doi:
229 10.1093/infdis/133.5.493. PubMed PMID: 1262715.
- 230 60. Mann JM, Moskowitz R. Plague and Pregnancy: A Case Report. *JAMA*. 1977;237(17):1854-5.
231 doi: 10.1001/jama.1977.03270440044020.
- 232 61. von Reyn CF, Weber NS, Tempest B, Barnes AM, Poland JD, Boyce JM, et al. Epidemiologic
233 and clinical features of an outbreak of bubonic plague in New Mexico. *J Infect Dis*. 1977;136(4):489-
234 94. Epub 1977/10/01. doi: 10.1093/infdis/136.4.489. PubMed PMID: 908848.
- 235 62. Plague — Arizona, Colorado, New Mexico. Morbidity and Mortality Weekly Report.
236 1977;26(26):215-6.
- 237 63. Plague — United States. Morbidity and Mortality Weekly Report. 1977;26(41):337-.
- 238 64. Plague — Arizona, California, New Mexico. Morbidity and Mortality Weekly Report.
239 1978;27(30):259-60.

- 240 65. Hoffman SL. Plague in the United States: the "black death" is still alive. *Ann Emerg Med*.
241 1980;9(6):319-22. Epub 1980/06/01. doi: 10.1016/s0196-0644(80)80068-0. PubMed PMID: 7386958.
- 242 66. Plague — United States, 1980. *Morbidity and Mortality Weekly Report*. 1980;29(31):371-7.
- 243 67. Human Plague — Texas, New Mexico. *Morbidity and Mortality Weekly Report*.
244 1981;30(12):137-8.
- 245 68. Human Plague Associated with Domestic Cats — California, Colorado. *Morbidity and*
246 *Mortality Weekly Report*. 1981;30(22):265-6.
- 247 69. Mann JM, Schmid GP, Stoesz PA, Skinner MD, Kaufmann AF. Peripatetic Plague. *JAMA*.
248 1982;247(1):47-8. doi: 10.1001/jama.1982.03320260031024.
- 249 70. Mann JM, Shaw RF. Febrile lymphadenitis in the American West. *Hosp Pract (Off Ed)*.
250 1983;18(1):51, 4, 6. Epub 1983/01/01. doi: 10.1080/21548331.1983.11702452. PubMed PMID:
251 6401271.
- 252 71. Plague — South Carolina. *Morbidity and Mortality Weekly Report*. 1983;32(32):417-8.
- 253 72. Barnes AM, Poland JD. Plague in the United States, 1982. *Morbidity and Mortality Weekly*
254 *Report: Surveillance Summaries*. 1983;32(3SS):19SS-24SS.
- 255 73. Plague Pneumonia — California. *Morbidity and Mortality Weekly Report*. 1984;33(34):481-3.
- 256 74. Winter plague--Colorado, Washington, Texas, 1983-1984. *MMWR Morb Mortal Wkly Rep*.
257 1984;33(11):145-8. Epub 1984/03/23. PubMed PMID: 6422229.
- 258 75. Weniger BG, Warren AJ, Forseth V, Shipps GW, Creelman T, Gorton J, et al. Human bubonic
259 plague transmitted by a domestic cat scratch. *Jama*. 1984;251(7):927-8. Epub 1984/02/17. PubMed
260 PMID: 6694293.
- 261 76. Welty TK, Grabman J, Kompare E, Wood G, Welty E, Van Duzen J, et al. Nineteen cases of
262 plague in Arizona. A spectrum including ecthyma gangrenosum due to plague and plague in
263 pregnancy. *West J Med*. 1985;142(5):641-6. Epub 1985/05/01. PubMed PMID: 4013279; PubMed
264 Central PMCID: PMCPMC1306131.
- 265 77. Florman AL, Spencer RR, Sheward S. Multiple lung cavities in a 12-year-old girl with bubonic
266 plague, sepsis, and secondary pneumonia. *Am J Med*. 1986;80(6):1191-3. Epub 1986/06/01. doi:
267 10.1016/0002-9343(86)90684-4. PubMed PMID: 3728514.
- 268 78. Hull HF, Montes JM, Mann JM. Plague masquerading as gastrointestinal illness. *West J Med*.
269 1986;145(4):485-7. Epub 1986/10/01. PubMed PMID: 3788132; PubMed Central PMCID:
270 PMCPMC1306978.
- 271 79. Wong TW. Plague in a pregnant patient. *Trop Doct*. 1986;16(4):187-9. Epub 1986/10/01. doi:
272 10.1177/004947558601600418. PubMed PMID: 3775853.
- 273 80. Becker TM, Poland JD, Quan TJ, White ME, Mann JM, Barnes AM. Plague meningitis--a
274 retrospective analysis of cases reported in the United States, 1970-1979. *West J Med*.
275 1987;147(5):554-7. Epub 1987/11/01. PubMed PMID: 3424819; PubMed Central PMCID:
276 PMCPMC1025943.
- 277 81. Moreno AJ, Reeves TA, Rodriguez AA, Turnbull GL. Imaging in plague. *Eur J Nucl Med*.
278 1987;13(6):315-7. Epub 1987/01/01. doi: 10.1007/bf00256560. PubMed PMID: 3665983.
- 279 82. Human Plague — United States, 1988. *Morbidity and Mortality Weekly Report*.
280 1988;37(42):653-6.
- 281 83. Imported bubonic plague--District of Columbia. *MMWR Morb Mortal Wkly Rep*.
282 1990;39(49):895, 901. Epub 1990/12/14. PubMed PMID: 2123285.
- 283 84. Migden D. Bubonic plague in a child presenting with fever and altered mental status. *Ann*
284 *Emerg Med*. 1990;19(2):207-9. Epub 1990/02/01. doi: 10.1016/s0196-0644(05)81811-6. PubMed
285 PMID: 2301801.
- 286 85. Owens C. Plague in New Mexico. *Journal of Community Health Nursing*. 1990;7(3):153-8.
- 287 86. Crook LD, Tempest B. Plague. A clinical review of 27 cases. *Arch Intern Med*.
288 1992;152(6):1253-6. Epub 1992/06/01. doi: 10.1001/archinte.152.6.1253. PubMed PMID: 1599354.
- 289 87. McClean KL. An outbreak of plague in northwestern province, Zambia. *Clin Infect Dis*.
290 1995;21(3):650-2. Epub 1995/09/01. doi: 10.1093/clinids/21.3.650. PubMed PMID: 8527559.

- 291 88. Fatal human plague--Arizona and Colorado, 1996. *MMWR Morb Mortal Wkly Rep.*
292 1997;46(27):617-20. Epub 1997/07/11. PubMed PMID: 9218646.
- 293 89. Chanteau S, Ratsitorahina M, Rahalison L, Rasoamanana B, Chan F, Boisier P, et al. Current
294 epidemiology of human plague in Madagascar. *Microbes Infect.* 2000;2(1):25-31. Epub 2000/03/16.
295 doi: 10.1016/s1286-4579(00)00289-6. PubMed PMID: 10717537.
- 296 90. Gage KL, Dennis DT, Orloski KA, Ettestad P, Brown TL, Reynolds PJ, et al. Cases of cat-
297 associated human plague in the Western US, 1977-1998. *Clin Infect Dis.* 2000;30(6):893-900. Epub
298 2000/06/15. doi: 10.1086/313804. PubMed PMID: 10852811.
- 299 91. Imported plague--New York City, 2002. *MMWR Morb Mortal Wkly Rep.* 2003;52(31):725-8.
300 Epub 2003/08/09. PubMed PMID: 12904738.
- 301 92. Chmura K, Cool C, Kircher T, Chan ED. Painful lymphadenopathy and fulminant sepsis in a
302 previously healthy 16-year-old girl. *Chest.* 2003;124(1):379-82. Epub 2003/07/11. doi:
303 10.1378/chest.124.1.379. PubMed PMID: 12853549.
- 304 93. Boulanger LL, Ettestad P, Fogarty JD, Dennis DT, Romig D, Mertz G. Gentamicin and
305 tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999. *Clin*
306 *Infect Dis.* 2004;38(5):663-9. Epub 2004/02/27. doi: 10.1086/381545. PubMed PMID: 14986250.
- 307 94. Human plague--four states, 2006. *MMWR Morb Mortal Wkly Rep.* 2006;55(34):940-3. Epub
308 2006/09/01. PubMed PMID: 16943764.
- 309 95. Notes from the field: two cases of human plague--Oregon, 2010. *MMWR Morb Mortal Wkly*
310 *Rep.* 2011;60(7):214. Epub 2011/02/25. PubMed PMID: 21346709.
- 311 96. Tourdjman M, Ibraheem M, Brett M, Debess E, Progulske B, Ettestad P, et al.
312 Misidentification of *Yersinia pestis* by automated systems, resulting in delayed diagnoses of human
313 plague infections--Oregon and New Mexico, 2010-2011. *Clin Infect Dis.* 2012;55(7):e58-60. Epub
314 2012/06/21. doi: 10.1093/cid/cis578. PubMed PMID: 22715170.
- 315 97. Cabanel N, Leclercq A, Chenal-Francois V, Annajar B, Rajerison M, Bekkhoucha S, et al.
316 Plague outbreak in Libya, 2009, unrelated to plague in Algeria. *Emerg Infect Dis.* 2013;19(2):230-6.
317 Epub 2013/01/26. doi: 10.3201/eid1902.121031. PubMed PMID: 23347743; PubMed Central PMCID:
318 PMC3559055.
- 319 98. Sinyange N, Kumar R, Inambao A, Moonde L, Chama J, Banda M, et al. Outbreak of Plague in
320 a High Malaria Endemic Region - Nyimba District, Zambia, March-May 2015. *MMWR Morb Mortal*
321 *Wkly Rep.* 2016;65(31):807-11. Epub 2016/08/12. doi: 10.15585/mmwr.mm6531a4. PubMed PMID:
322 27513350.
- 323 99. Melman SD, Ettestad PE, VinHatton ES, Ragsdale JM, Takacs N, Onischuk LM, et al. Human
324 case of bubonic plague resulting from the bite of a wild Gunnison's prairie dog during translocation
325 from a plague-endemic area. *Zoonoses Public Health.* 2018;65(1):e254-e8. Epub 2017/11/08. doi:
326 10.1111/zph.12419. PubMed PMID: 29110441; PubMed Central PMCID: PMC5859330.
- 327 100. Kehrmann J, Popp W, Delgermaa B, Otgonbayar D, Gantumur T, Buer J, et al. Two fatal cases
328 of plague after consumption of raw marmot organs. *Emerg Microbes Infect.* 2020;9(1):1878-80.
329 Epub 2020/08/09. doi: 10.1080/22221751.2020.1807412. PubMed PMID: 32762515; PubMed
330 Central PMCID: PMC7473306.
- 331 101. Dale AP, Kretschmer M, Ruberto I, Wagner DM, Solomon C, Komatsu K, et al. Notes from the
332 Field: Delays in Identification and Treatment of a Case of Septicemic Plague - Navajo County,
333 Arizona, 2020. *MMWR Morb Mortal Wkly Rep.* 2021;70(31):1063-4. Epub 2021/08/06. doi:
334 10.15585/mmwr.mm7031a1. PubMed PMID: 34351879; PubMed Central PMCID: PMC8367317
- 335 Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest
336 were disclosed.
- 337 102. Andrianaivoarimanana V, Piola P, Wagner DM, Rakotomanana F, Maheriniaina V,
338 Andrianalimanana S, et al. Trends of Human Plague, Madagascar, 1998-2016. *Emerg Infect Dis.*
339 2019;25(2):220-8. Epub 2019/01/23. doi: 10.3201/eid2502.171974. PubMed PMID: 30666930;
340 PubMed Central PMCID: PMC6346457.

- 341 103. Randremanana RV, Raberahona M, Randria MJD, Rajerison M, Andrianaivoarimanana V,
342 Legrand A, et al. An open-label, randomized, non-inferiority trial of the efficacy and safety of
343 ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY):
344 study protocol for a randomized control trial. *Trials*. 2020;21(1):722. Epub 2020/08/19. doi:
345 10.1186/s13063-020-04642-2. PubMed PMID: 32807214; PubMed Central PMCID:
346 PMCPMC7429934.
- 347 104. Bourner J, Salam AP, Jaspard M, Olayinka A, Fritzell C, Goncalves B, et al. The West Africa
348 Lassa fever Consortium pre-positioned protocol for a Phase II/III adaptive, randomised, controlled,
349 platform trial to evaluate multiple Lassa fever therapeutics. *Wellcome Open Research*. 2023.

350

Identification of studies via databases and registers



